Weekly Investment Analysts’ Ratings Changes for INC Research Holdings (INCR)

Several brokerages have updated their recommendations and price targets on shares of INC Research Holdings (NASDAQ: INCR) in the last few weeks:

• 12/5/2016 – INC Research Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/30/2016 – INC Research Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/30/2016 – INC Research Holdings was upgraded by analysts at TheStreet from a “hold” rating to a “buy” rating.
• 11/23/2016 – INC Research Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/22/2016 – INC Research Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $57.00 price target on the stock. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/14/2016 – INC Research Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $57.00 price target on the stock. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/11/2016 – INC Research Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
• 11/1/2016 – INC Research Holdings had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $56.00 price target on the stock.

INC Research Holdings Inc. (NASDAQ:INCR) traded down 0.39% during mid-day trading on Wednesday, reaching $51.10. 107,977 shares of the company were exchanged. INC Research Holdings Inc. has a one year low of $34.19 and a one year high of $57.11. The stock has a market capitalization of $2.74 billion, a price-to-earnings ratio of 27.12 and a beta of 1.76. The stock has a 50 day moving average of $48.59 and a 200-day moving average of $44.49.

INC Research Holdings (NASDAQ:INCR) last announced its quarterly earnings results on Monday, October 31st. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.01. The firm had revenue of $259.56 million for the quarter, compared to the consensus estimate of $259.89 million. INC Research Holdings had a net margin of 6.58% and a return on equity of 49.42%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.58 EPS. On average, equities analysts expect that INC Research Holdings Inc. will post $2.50 earnings per share for the current fiscal year.

In other news, CEO D. Jamie Macdonald sold 53,970 shares of the firm’s stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of $44.30, for a total transaction of $2,390,871.00. Following the sale, the chief executive officer now owns 62,220 shares of the company’s stock, valued at approximately $2,756,346. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert W. Breckon sold 12,197 shares of the firm’s stock in a transaction dated Monday, September 26th. The shares were sold at an average price of $44.16, for a total transaction of $538,619.52. Following the sale, the director now directly owns 15,561 shares in the company, valued at approximately $687,173.76. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.

INC Research Holdings, Inc is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.